There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19)
vaccines and vaccine effectiveness (VE) of booster doses. Using linked national …

Background Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with
decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and …

Background New approaches and tools were needed to support the strategic planning,
implementation and management of a Program launched by the Brazilian Government to fund …

Background The elimination strategy reduced known leprosy prevalence but the detection
rate remains high in many countries, including Brazil. The high Brazilian detection rate …

Background Social determinants can affect the transmission of leprosy and its progression
to disease. Not much is known about the effectiveness of welfare and primary health care …

Leprosy is a chronic, infectious disease caused by Mycobacterium leprae. It mainly affects
the peripheral nervous system, skin, and certain other tissues such as the reticulo-endothelial …

Over 200,000 new cases of leprosy are detected each year, of which approximately 7% are
associated with grade-2 disabilities (G2Ds). For achieving leprosy elimination, one of the …

Background Aging influences COVID-19 severity and response to vaccination, but previous
vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within …

Background Although leprosy is recognised as a disease of poverty, there is little evidence
on the specific socioeconomic factors associated with disease risk. To inform targeted …

Although severe COVID-19 in children is rare, they may develop multisystem inflammatory
syndrome, long-COVID and downstream effects of COVID-19, including social isolation and …